Wael Khreisat
Biographic Data
| ID | 8267147 |
|---|---|
| NAME | Wael Khreisat |
| GIVEN NAMES | Wael |
| FAMILY NAME | Khreisat |
| SIGNATURE | KHREISAT W |
| AFFILIATIONS | King Hussein Medical Center |
| ORCID | 0000-0002-0422-6467 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 3–6-Year-Old Children with Autism Spectrum Disorder
Atomoxetine is indicated for the management of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years. Few studies have assessed the safety and tolerability of atomoxetine in younger patients. This retrospective cohort study included 133 children aged 3-6 years who were diagnosed with ADHD comorbid with autism spectrum disorder (ASD). The primary endpoint was the evaluation of the safety profile of atomoxet…
No prominent works on this page.
Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 3–6-Year-Old Children with Autism Spectrum Disorder
Atomoxetine is indicated for the management of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years. Few studies have assessed the safety and tolerability of atomoxetine in younger patients. This retrospective cohort study included 133 children aged 3-6 years who were diagnosed with ADHD comorbid with autism spectrum disorder (ASD). The primary endpoint was the evaluation of the safety profile of atomoxet…
Adverse effect (1 work) · Atomoxetine (1 work) · Attention Deficit Hyperactivity Disorder (1 work) · Autism (1 work) · Autism spectrum disorder (1 work) · Autism Spectrum Disorder Research (1 work) · Child and Adolescent Psychosocial and Emotional Development (1 work) · Cohort (1 work) · Comorbidity (1 work) · Discontinuation (1 work)